Contact Information
Norris Comprehensive Cancer Center
1441 Eastlake Avenue
Los Angeles, CA 90033
01. Mesothelioma Care
Mesothelioma Care at University of Southern California (USC)
A National Cancer Institute-designated Comprehensive Cancer facility, the Norris Comprehensive Cancer Center at the University of Southern California is a leader in both patient care and cancer research, offering the expertise of the scientists and physicians at USC’s Keck School of Medicine combined with the latest cutting-edge technology available to aid in the diagnosis, treatment and prevention of all types of cancer, like mesothelioma.
If qualified, cancer patients at Norris are offered participation in any number of clinical trials that are being conducted at the facility at any given time. The hospital’s teams of experts can determine whether or not their patients are eligible for consideration for these studies, which test new drugs (like Carboplatin, Gemcitabine and Alimta®) and treatments for cancer. Clinical trials offered at USC/Norris Comprehensive Cancer Center are due to being awarded numerous grants, totaling more than $85 million.
Additionally, the researchers at Norris are divided into five thematic programs, which allow them to quickly bring their findings to the patients at the facility. These programs include molecular genetics, epigenetics and regulation, tumor microenvironment, cancer epidemiology and cancer control research.
02. Specializations
University of Southern California (USC) Specializations
- Cancer epidemiology
- Clinical trials
- Clinical oncology
- Tumor microenvironment
03. Accreditations
University of Southern California (USC) Accreditations
- National Cancer Institute Designated Comprehensive Cancer Center
04. Mesothelioma Clinical Trials
Mesothelioma Clinical Trials at University of Southern California (USC)
The following clinical trials are in progress or actively recruiting participants at University of Southern California (USC):
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Conditions: Carcinoma, Neoplasms, Carcinoma, Squamous Cell, Adenocarcinoma, Neoplasms, Germ Cell and Embryonal, Mesothelioma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Carcinoma, Basal Cell, Gastrointestinal Stromal Tumors, Carcinoid Tumor, Carcinoma, Transitional Cell, Carcinoma, Adenoid Cystic, Adenocarcinoma of Lung, Teratoma, Carcinoma, Neuroendocrine, Pheochromocytoma, Seminoma, Cystadenocarcinoma, Serous, Choriocarcinoma, Carcinoma, Endometrioid, Cystadenocarcinoma, Paraganglioma, Chordoma, Hemangiosarcoma, Fibromatosis, Aggressive, Adenocarcinoma, Mucinous, Nerve Sheath Neoplasms, Trophoblastic Neoplasms, Gestational Trophoblastic Disease, Neurofibrosarcoma, Thyroid Neoplasms, Fibroma, Cystadenocarcinoma, Mucinous, Pseudomyxoma Peritonei, Vulvar Neoplasms, Sex Cord-Gonadal Stromal Tumors, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Paget Disease, Extramammary, Adenocarcinoma, Papillary, Carcinoma, Acinar Cell, Adenocarcinoma, Bronchiolo-Alveolar, Neoplasms, Unknown Primary, Mixed Tumor, Mullerian, Carcinoma, Giant Cell, Adenocarcinoma, Clear Cell
Last Updated: October 31, 2022
Status: Recruiting
Locations: Birmingham, AL. Mobile, AL. Anchorage, AK.
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
Conditions: Mesothelioma, Mesothelioma, Malignant
Last Updated: December 2, 2021
Status: Recruiting
Locations: Birmingham, AL. Phoenix, AZ. Scottsdale, AZ. Duarte, CA. La Jolla, CA. Los Angeles, CA. Los Angeles, CA. Newport Beach, CA. Aurora, CO. Aventura, FL. Coral Gables, FL. Deerfield Beach, FL. Jacksonville, FL. Miami, FL. Miami, FL. Plantation, FL. Chicago, IL. Chicago, IL. Lexington, KY. Baltimore, MD. Baltimore, MD. Boston, MA. Boston, MA. Rochester, MN. Creve Coeur, MO. Saint Louis, MO. Saint Louis, MO. Saint Peters, MO. Durham, NC. Pittsburgh, PA. Dallas, TX. Salt Lake City, UT.
